Edition:
United Kingdom

Allena Pharmaceuticals Inc (ALNA.OQ)

ALNA.OQ on NASDAQ Stock Exchange Global Select Market

16.02USD
22 May 2018
Change (% chg)

$0.03 (+0.19%)
Prev Close
$15.99
Open
$16.02
Day's High
$16.02
Day's Low
$16.02
Volume
420
Avg. Vol
23,116
52-wk High
$17.55
52-wk Low
$6.15

Chart for

About

Allena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II... (more)

Overall

Beta: --
Market Cap(Mil.): $305.47
Shares Outstanding(Mil.): 20.70
Dividend: --
Yield (%): --

Financials

  ALNA.OQ Industry Sector
P/E (TTM): -- 237.88 32.90
EPS (TTM): -1.16 -- --
ROI: -- -7.38 12.74
ROE: -- -10.11 14.64

BRIEF-Allena Pharmaceuticals Reports Q1 Loss Per Share $0.38

* ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

08 May 2018

BRIEF-Allena Pharmaceuticals Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $0.48

* ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

27 Mar 2018

BRIEF-Allena Pharmaceuticals Initiates First Phase 3 Trial For ALLN-177 In Patients With Enteric Hyperoxaluria

* ALLENA PHARMACEUTICALS INITIATES FIRST PHASE 3 TRIAL FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA

06 Mar 2018

Earnings vs. Estimates